FLEX Pharma Inc (fka FLKS)

[CrazyC]

8-K out... Not enough votes just yet and next meeting set for July 12, 2019...

https://www.sec.gov/Archives/edgar/data/1615219/000119312519173832/d746827d8k.htm

Item 5.07
Submission of Matters to a Vote of Security Holders.

On June 14, 2019, Flex Pharma, Inc. (“Flex Pharma” or “FLKS”) held its special meeting of stockholders. The purpose of the special meeting is described in Flex Pharma’s definitive proxy statement/prospectus/information statement dated April 29, 2019 (the “Proxy Statement”) relating to the pending merger with Salarius Pharmaceuticals, LLC (“Salarius”), which Flex Pharma first mailed to its stockholders on or about May 3, 2019.

At the special meeting, Flex Pharma determined that a quorum of stockholders was not present in person or by duly authorized proxy to transact business at the meeting and Flex Pharma adjourned the meeting. Flex Pharma announced that the adjourned meeting will be reconvened at the offices of Cooley LLP, 500 Boylston Street, 14th Floor, Boston, MA 02116, at 10:00 A.M. local time, on July 12, 2019.

Item 7.01
Regulation FD Disclosure.

Approximately 85% of shares voted by Flex Pharma’s stockholders to date support the merger. Flex believes this strong support is due to:

• recommendations by Institutional Shareholder Services (ISS) and Glass-Lewis (two leading U.S. institutional voting advisory services) to vote “FOR” each of the proposals in the Proxy Statement;

• ISS’s statement that “[t]he proposed transaction with Salarius appears to offer FLKS shareholders a better potential outcome than FLKS’ standalone business”;

• a unanimous recommendation by Flex Pharma’s board of directors to vote “FOR” each of the proposals; and

• the merger offering great future potential for Flex Pharma’s stockholders based on Salarius’ clinical pipeline, targeting a rare, orphan cancer with no targeted treatments and cancers with high unmet need using an epigenetic approach.

Flex Pharma urges stockholders to support the merger by voting as soon as possible FOR all the proposals in the Proxy Statement. Failure to vote, or a vote against any proposal, puts the merger at risk.

If Flex Pharma does not complete the merger, Flex Pharma likely will dissolve, liquidate or wind-up, and stockholders will likely lose most of the value of their investment.

Stockholders can vote by telephone, via the Internet or using the proxy card they received with their proxy materials. For any questions, or assistance in voting shares, or to receive additional copies of the proxy materials, stockholders should call proxy solicitor Innisfree M&A Inc., toll-free at 1 [phone].